ALNY
Alnylam Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$266.11
+0.61%Margins
Gross margin
79.7%
EBITDA margin
23.9%
EBIT margin
20.8%
Net margin
16.8%
FCF margin
11.3%
59.7%
Return on equity
14.5%
Return on assets
38.1%
Return on invested capital
0.90x
Asset turnover
$634.5M
Cash from operations
$25
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026